L. Roy Papp & Associates LLP Has $22.74 Million Stock Holdings in Stryker Co. (NYSE:SYK)

L. Roy Papp & Associates LLP lessened its stake in shares of Stryker Co. (NYSE:SYK) by 0.1% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 62,951 shares of the medical technology company’s stock after selling 81 shares during the quarter. Stryker comprises about 2.8% of L. Roy Papp & Associates LLP’s portfolio, making the stock its 11th largest holding. L. Roy Papp & Associates LLP’s holdings in Stryker were worth $22,742,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Wealthcare Advisory Partners LLC raised its stake in Stryker by 41.4% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 1,049 shares of the medical technology company’s stock worth $375,000 after purchasing an additional 307 shares in the last quarter. Kathmere Capital Management LLC acquired a new stake in Stryker in the 1st quarter worth about $203,000. Hennion & Walsh Asset Management Inc. raised its stake in Stryker by 74.7% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 4,915 shares of the medical technology company’s stock worth $1,759,000 after purchasing an additional 2,102 shares in the last quarter. Vicus Capital acquired a new stake in Stryker in the 1st quarter worth about $618,000. Finally, Cornerstone Wealth Group LLC raised its stake in Stryker by 32.0% in the 1st quarter. Cornerstone Wealth Group LLC now owns 2,287 shares of the medical technology company’s stock worth $818,000 after purchasing an additional 554 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 2.0 %

SYK traded down $7.08 during trading on Friday, reaching $352.82. 1,244,464 shares of the company’s stock were exchanged, compared to its average volume of 1,247,738. Stryker Co. has a one year low of $255.22 and a one year high of $374.63. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $134.41 billion, a PE ratio of 40.28, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91. The firm has a fifty day moving average price of $358.80 and a two-hundred day moving average price of $343.67.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company had revenue of $5.42 billion for the quarter, compared to analyst estimates of $5.40 billion. During the same period in the prior year, the firm posted $2.54 EPS. The company’s quarterly revenue was up 8.5% on a year-over-year basis. As a group, equities research analysts forecast that Stryker Co. will post 12 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.80 per share. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.91%. Stryker’s payout ratio is presently 36.53%.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 2,121 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now owns 10,042 shares in the company, valued at $3,715,540. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Stryker news, insider Viju Menon sold 600 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 2,121 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,715,540. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 220,068 shares of company stock worth $71,811,372 in the last quarter. Company insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of several analyst reports. Morgan Stanley boosted their target price on shares of Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Truist Financial boosted their target price on shares of Stryker from $345.00 to $370.00 and gave the company a “hold” rating in a research report on Monday, October 14th. BTIG Research boosted their target price on shares of Stryker from $374.00 to $383.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Needham & Company LLC boosted their target price on shares of Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Finally, Stifel Nicolaus dropped their target price on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $381.16.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.